Pharvaris director sells 32,900 shares in 10b5-1 plan

Pharvaris N.V. director Johannes Schikan reported open-market sales of a total of 32,900 shares of common stock.

Rhea-AI Filing Summary

Pharvaris N.V. director Johannes Schikan reported open-market sales of a total of 32,900 shares of common stock. The sales occurred on April 29–30 at weighted average prices of $30.07, $30.30, and $31.03 per share under a pre-set Rule 10b5-1 trading plan. After these transactions, he directly holds 355,167 shares, indicating the sales represent a relatively small portion of his overall position and appear to be routine, pre-planned disposals rather than discretionary trades.

Insider Trade Summary 10b5-1

Net Seller: 32,900 shares

Net Sell 3 txns

Insider Schikan Johannes Gerardus Christiaan Petrus

Role Director

Sold 32,900 shs ($997K)

Type	Security	Shares	Price	Value
Sale	Common Stock	28,400	$30.3024	$861K
Sale	Common Stock	670	$31.0321	$21K
Sale	Common Stock	3,830	$30.0692	$115K

Holdings After Transaction: Common Stock — 355,167 shares (Direct)

Footnotes (4)

1. F1. This is a scheduled sale from 10b5-1 trading plan.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. F3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
4. F4. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $31.03 to $31.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Key Figures

Total shares sold: 32,900 shares Sale price 1: $30.0692 per share Sale price 2: $30.3024 per share +3 more

6 metrics

Total shares sold 32,900 shares Aggregate open-market sales reported in this Form 4

Sale price 1 $30.0692 per share Weighted average price for 3,830 shares sold on April 29

Sale price 2 $30.3024 per share Weighted average price for 28,400 shares sold on April 30

Sale price 3 $31.0321 per share Weighted average price for 670 shares sold on April 30

Shares owned after trades 355,167 shares Director’s direct holdings following the reported sales

Net buy/sell direction 32,900 share net sale transactionSummary shows net-sell across three transactions

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, restricted stock units, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions on the reported date pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold"

restricted stock units financial

"shares of common stock acquired upon vesting of restricted stock units on various dates"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Pharvaris (PHVS) director report in this Form 4 filing?

The Form 4 shows Pharvaris director Johannes Schikan sold 32,900 common shares in open-market trades. These transactions were executed under a Rule 10b5-1 trading plan and left him holding 355,167 shares directly after the reported sales.

How many Pharvaris (PHVS) shares did the director sell and at what prices?

Johannes Schikan sold 32,900 Pharvaris shares across three transactions. Weighted average sale prices were approximately $30.07, $30.30, and $31.03 per share, reflecting multiple trades within narrow price ranges on April 29 and April 30.

How many Pharvaris (PHVS) shares does the director still own after the sales?

Following the reported transactions, Johannes Schikan directly owns 355,167 Pharvaris common shares. This figure comes from the post-transaction holdings reported in the Form 4 and indicates he retained a substantial equity position after completing the 10b5-1 plan sales.

Were the Pharvaris (PHVS) insider sales pre-planned under a Rule 10b5-1 plan?

Yes. Footnotes explain the sales were executed pursuant to a Rule 10b5-1 trading plan. Such plans are established in advance and automate trading, which can make the timing of individual transactions less indicative of the insider’s current market outlook.

Do the Pharvaris (PHVS) insider sales involve shares from vested restricted stock units?

The filing states the sold shares include stock acquired upon vesting of restricted stock units. These RSU-based holdings had vested on various dates, and the director subsequently sold some of those shares through the pre-arranged 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 07:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schikan Johannes Gerardus Christiaan Petrus

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026		S(1)		3,830	D	$30.0692(2)	384,237	D
Common Stock	04/30/2026		S(1)		28,400	D	$30.3024(3)	355,837	D
Common Stock	04/30/2026		S(1)		670	D	$31.0321(4)	355,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This is a scheduled sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

4. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $31.03 to $31.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

	/s/ Marnus Nel, Attorney-in-Fact for Johannes Schikan	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)